



The Organization

The Cancer Research Institute (CRI), established in 1953 and headquartered in New York City, is the preeminent U.S. nonprofit organization dedicated to saving more lives by fueling the discovery and development of powerful immunotherapies for all cancers. Guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and 35 members of the National Academy of Sciences, CRI has invested over \$517 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. The Cancer Research Institute's research funding supports the entire continuum of basic discovery through early-stage clinical development of novel cancer immunotherapies.

The Opportunity: Research Analyst, Clinical Accelerator and Venture Fund

The role offers this high-performing individual the opportunity to work in a wellcapitalized nonprofit organization and to lead work that will have a direct impact on the development of potentially curative treatments for all types of cancer. The Research Analyst will be able to collaborate with CRI's scientific leadership as well as pharmaceutical, biotechnology, clinical trial management partners, and venture capital investors. The individual will also be able to stay on top of key immunotherapy trends and developments in oncology.

The Research Analyst will be an integral team member of one of CRI's flagship programs, the Clinical Accelerator, a unique nonprofit-academia-industry collaboration model that serves as a synergistic "incubator" for multi-center clinical trials testing promising new cancer immunotherapy combinations in areas of high unmet medical need. CRI partners with leading clinician/researchers, biopharmaceutical companies, and nonprofit partners to develop new study concepts and conduct such studies. The Clinical Accelerator team leads the entire process, including sourcing new study ideas, business development-related activities including sourcing new drugs and study funding, design of the clinical study and translational research plans, execution/oversite of the clinical trial, and driving the publication strategy. The program provides philanthropic investment and clinical resources to accelerate the clinical development of CRI-supported clinical studies. The Clinical Accelerator team is also responsible for leading and managing CRI's venture investment practice, including souring new opportunities, conducting due diligence, liaising with existing and potential investors, and managing the CRI investment portfolio.

Working closely with the Clinical Accelerator's leadership, the successful candidate will be an integral part of the program's scientific diligence efforts, including:

Cancer Research Institute[™]

- Anna-Maria Kellen Clinical Accelerator
- Reviewing and evaluating scientific posters, publications, websites, and confidential preclinical/clinical data from pharmaceutical and biotechnology companies;
- Liaising with CROs, clinical teams, and company partners to review and select novel drug combinations to be tested in CRI clinical trials;
- Monitoring and assisting in coordinating clinical trial design and correlative research strategies of CRI clinical trials;
- Monitoring the immune-oncology drug development competitive landscape to generate new, field-wide analyses that will help guide the evolution of CRI's overall program strategies;
- Updating the Clinical Accelerator's IO landscape database and leading publication of the update;
- Collaborating with team members and partners on the publication of additional research in leading academic or trade journals;
- Assisting in completing ad hoc consulting assignments;
- Attending and reporting on scientific/industry conferences, i.e. ASCO, AACR, and SITC, and medical meetings; and
- Assisting with the due diligence and evaluation on new venture investing opportunities as well as monitoring CRI's venture investment portfolio.

Professional Experience

- An advanced technical degree (Ph.D., M.D., or equivalent) in immunology, cancer immunotherapy or relevant cancer research field is required;
- 2+ years of postdoctoral or industry experience in cancer immunology or immuno-oncology is highly preferred;
- An advanced, deep, and current understanding of the basic and clinical science of cancer immunology, exemplified by outstanding publications;
- Strong analytical skills, e.g., excellence in self-guided research, proficiency in statistics, skillful in Excel, PowerPoint, and other equivalent data analytical tools or software;
- Experience with data science (e.g., Python, R, SQL, or equivalent) is highly desired;
- Strong interpersonal skills and ability to work effectively either in a team or independently;
- A high degree of proven written and verbal communication skills; and
- Must be comfortable in a hands-on, self-guided, and self-started work environment:
 - Must be able to work effectively with timelines and high workloads (time management), and have a level of sophistication that would be typical of research analyst/healthcare consulting roles in for-profit companies in healthcare industry;
 - Previous exposure to clinical drug development, clinical studies and regulatory affairs is a plus but not required; and

CRI Cancer Research Institute[™]

- Anna-Maria Kellen Clinical Accelerator
- Previous exposure to life science diligence, investments and intellectual property is a plus, but not required.

Personal Characteristics

- Motivated by CRI's mission to turn cancer into a curable disease;
- Thrive in a collaborative team environment;
- Desire to learn and comfortable asking questions, solving complex problems proactively and autonomously;
- The highest standard of professionalism;
- High work integrity with attention to details;
- A collaborative, personable, and adaptable personality; and
- Comfortable working regularly with off-site colleagues/clients over email, phone, or other remote technologies.

Compensation

Cancer Research Institute is prepared to offer the successful candidate a competitive compensation package that includes a base salary of between \$95,000 – \$115,000, comprehensive health insurance, generous retirement benefits, and potential for performance-based bonuses, similar to those of for-profit organizations.

Work Location

Current work policy requires staff to be in the office in lower Manhattan every Wednesday and ability to work remotely Monday, Tuesday, Thursday, and Friday.

Contact

Please send cover letter and resume to:

Jay Campbell Managing Director, Clinical Accelerator and Venture Fund Cancer Research Institute 29 Broadway, Floor 4 New York, NY 10006 jcampbell@cancerresearch.org